Zobrazeno 1 - 10
of 22
pro vyhledávání: '"T S Salnikova"'
Autor:
A E Karateev, E Yu Pogozheva, E A Filatova, V N Amirjanova, A M Lila, O V Antipova, A R Babaeva, A V Volkorezova, A F Davydova, V G Davtyan, E V Zonova, O N Ivanova, N N Kalinina, N I Kiseleva, L A Knyazeva, A I Kulikov, O B Nesmeyanova, V I Mazurov, L V Masneva, L V Menshikova, I V Obuhova, E N Otteva, T S Salnikova, I N Shchendrygin, S P Yakupova
Publikováno v:
Терапевтический архив, Vol 90, Iss 6, Pp 65-73 (2018)
Non-steroidal anti-inflammatory drugs (NSAIDs) are most popular medications for the treatment of pain in common musculoskeletal diseases such as osteoarthritis (OA) and non-specific low back pain (LBP). However, the factors affecting the effectivenes
Externí odkaz:
https://doaj.org/article/e4a273b8b13b4eb68d62beba2d567eb5
Autor:
V N Sorolskaya, E. V. Kusnelsova, T S Salnikova, M. Y. Seregina, KB Taran, G. V. Petryaeva, O. V. Bogdanovich, A. V. Malistina, Y. V. Belokon, D. V. Seregin, L G Holodova
Publikováno v:
Научно-практическая ревматология, Vol 45, Iss 2, Pp 45-50 (2007)
Цель. Оценить эффективность, переносимость и безопасность магнитофореза мази «Хондроксид®» у пациентов с остеоартрозом (ОА) крупных су
Externí odkaz:
https://doaj.org/article/b24a5672aafa45c28730d67c9c7144eb
Autor:
T S Salnikova, R M Balabanova
Publikováno v:
Научно-практическая ревматология, Vol 41, Iss 4, Pp 44-48 (2003)
Objective. To assess early administration and efficacy of 3 disease modifying antirheumatic drugs. Material and methods. 92 pts with rheumatoid arthritis (RA) aged 17 to 45 years (mean age 34,9±8,5 years) were included. Disease duration did not exce
Externí odkaz:
https://doaj.org/article/a6493ca6c9bb492b88ccbb8d7a10bdda
Autor:
T S Salnikova, R M Balabanova
Publikováno v:
Научно-практическая ревматология, Vol 41, Iss 2, Pp 7-10 (2003)
Objective. To define the most important manifestations of early RA. Methods. 92 pts aged 17 to 45 years (mean 34,9 ±8,52 years) with RA of 2-3 activity degree diagnosed during the first months of the disease (mean 3,5 months), were investigated and
Externí odkaz:
https://doaj.org/article/b8fd9d410dcc420f936513e42f63dfdc
Autor:
R M Balabanova, T S Salnikova
Publikováno v:
Научно-практическая ревматология, Vol 39, Iss 5, Pp 87-91 (2001)
Ummary Objective. To reveal J'reguency of accompaning virus infection and possibility to use antivirus therapy together in therapy RA. Material. 40 patients with RA at the age of 17-45 were studied. The duration of disease was not more than 6 months;
Externí odkaz:
https://doaj.org/article/0db4c46e571f4683a57277c0fbabd05d
Autor:
A. E. Karateev, E. S. Filatova, E. Yu. Pogozheva, V. N. Amirdzhanova, E. L. Nasonov, A. M. Lila, V. I. Mazurov, A. Yu. De, A. A. Baranov, N. A. Lapkina, G. V. Lukina, N. A. Kiryukhina, S. Yu. Davidyan, T. S. Salnikova, R. R. Samigullina, D. S. Chakieva, I. M. Marusenko, O. V. Semagina, M. Yu. Semchenkova, A. F. Davydova, E. V. Kalinina
Publikováno v:
Современная ревматология, Vol 14, Iss 2, Pp 69-75 (2020)
Janus kinase (JK) inhibitors block the intracellular signaling pathways that are responsible for the synthesis of proinflammatory cytokines and mediators, which in turn cause the activation of pain receptors and central sensitization (CS). It is sugg
Externí odkaz:
https://doaj.org/article/af84c1d6e4e34c688e41f9ab87acd8f6
Autor:
V. N. Amirdzhanova, E. Yu. Pogozheva, A. E. Karateev, O. V. Antipova, I. B. Vinogradova, A. Yu. Kazankova, R. G. Mukhina, A. G. Vasilyev, O. B. Nesmeyanova, E. A. Bogdanova, R. R. Samigullina, A. A. Vasilenko, I. B. Bashkova, T. S. Salnikova, I. N. Dashkov, N. E. Nikulenkova, V. Yu. Manokhin, I. P. Afanasyeva, O. N. Anoshenkova, T. V. Plaksina, M. R. Spitsina, L. V. Solodovnikova, A. V. Petrov, O. P. Slyusar, E. V. Papichev, E. V. Ivanova, L. V. Masneva, L. P. Evstigneeva, I. V. Kolotilina, E. N. Otteva, I. A. Cherentsova, I. N. Shchendrygin, S. A. Derevenskikh, I. G. Bannikova, N. K. Delyavskaya, I. N. Danilova, I. M. Marusenko
Publikováno v:
Современная ревматология, Vol 13, Iss 3, Pp 30-38 (2019)
Objective: to assess quality-of-life (QoL) dynamics in patients with rheumatoid arthritis (RA) when initiating therapy with biological agents (BAs) in real clinical practice.Patients and methods. The investigation enrolled patients with RA from the p
Externí odkaz:
https://doaj.org/article/3606913e2b6f4d75804f536e5a45b4e7
Autor:
A. E. Karateev, E. Yu. Pogozheva, V. N. Amirjanova, E. S. Filatova, A. M. Lila, V. I. Mazurov, R. R. Samigullina, A. M. Dadalova, A. Yu. Dyo, D. S. Chakieva, A. A. Baranov, N. A. Lapkina, E. N. Koltsova, N. A. Kiryukhina, I. N. Shchendrigin, T. G. Rasevich, A. F. Davydova, I. V. Semizarova, I. A. Shafieva, I. B. Bashkova, D. A. Bobrikova, D. A. Murtazalieva, I. N. Kushnir, E. V. Kalinina, T. S. Salnikova, I. M. Marusenko, O. V. Semagina, I. B. Vinogradova, D. G. Krechikova, M. Yu. Semchenkova, E. L. Nasonov
Publikováno v:
Научно-практическая ревматология, Vol 59, Iss 4 (2021)
The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates the synthesis of cytokines and mediators involved in the development of pain and central sensitization (CS), which determines the rapid analgesic effect. H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54cb4b31383dd2c9bc7fc09d3b1a7336
https://rsp.mediar-press.net/rsp/article/view/3055
https://rsp.mediar-press.net/rsp/article/view/3055
Publikováno v:
Proceedings of the Second Conference on Sustainable Development: Industrial Future of Territories (IFT 2021).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b909cdbcb3ac991fbcb9028fe4ed823
https://doi.org/10.2991/aebmr.k.211118.046
https://doi.org/10.2991/aebmr.k.211118.046
Autor:
E. L. Nasonov, M. L. Stanislav, V. I. Mazurov, T. M. Chernykh, V. N. Sorotskaya, T. S. Salnikova, R. S. Saikovsky, O. V. Reshet’ko, T. A. Popova, E. I. Shmidt, V. P. Tyurin, N. P. Shilkina, I. N. Bokarev, M. Z. Kanevskaya, S. S. Yakushin
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 3, Pp 280-285 (2018)
Objective: to assess the long-term safety and efficiency of tocilizumab (TCZ) therapy in patients with early rheumatoid arthritis (RA) of moderate and high activity, who have completed the basic WA19926 study, as well as the rate of sustained drug-fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0253124db37803c90d8ff4812fe3ed1c
https://rsp.mediar-press.net/rsp/article/view/2560
https://rsp.mediar-press.net/rsp/article/view/2560